Division and Center for Evidence-Based Medicine and Outcomes Research, Department of Internal Medicine, Clinical and Translational Science Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
J Clin Epidemiol. 2012 Jun;65(6):602-9. doi: 10.1016/j.jclinepi.2011.10.016. Epub 2012 Mar 16.
To assess whether the reported methodological quality of randomized controlled trials (RCTs) reflects the actual methodological quality and to evaluate the association of effect size (ES) and sample size with methodological quality.
Systematic review. This is a retrospective analysis of all consecutive phase III RCTs published by eight National Cancer Institute Cooperative Groups up to 2006. Data were extracted from protocols (actual quality) and publications (reported quality) for each study.
Four hundred twenty-nine RCTs met the inclusion criteria. Overall reporting of methodological quality was poor and did not reflect the actual high methodological quality of RCTs. The results showed no association between sample size and actual methodological quality of a trial. Poor reporting of allocation concealment and blinding exaggerated the ES by 6% (ratio of hazard ratio [RHR]: 0.94; 95% confidence interval [CI]: 0.88, 0.99) and 24% (RHR: 1.24; 95% CI: 1.05, 1.43), respectively. However, actual quality assessment showed no association between ES and methodological quality.
The largest study to date shows that poor quality of reporting does not reflect the actual high methodological quality. Assessment of the impact of quality on the ES based on reported quality can produce misleading results.
评估随机对照试验(RCT)报告的方法学质量是否反映实际的方法学质量,并评估效应大小(ES)和样本量与方法学质量的关系。
系统评价。这是对截至 2006 年,由八个美国国立癌症研究所合作组发表的所有连续三期 RCT 的回顾性分析。从每个研究的方案(实际质量)和出版物(报告质量)中提取数据。
429 项 RCT 符合纳入标准。总体报告的方法学质量较差,并未反映 RCT 的实际高质量。结果显示,样本量与试验的实际方法学质量之间没有关联。分配隐匿和盲法的报告质量差,夸大了 ES 分别为 6%(风险比[RHR]:0.94;95%置信区间[CI]:0.88,0.99)和 24%(RHR:1.24;95% CI:1.05,1.43)。然而,实际质量评估显示 ES 与方法学质量之间没有关联。
迄今为止最大的研究表明,报告质量差并不反映实际的高质量。基于报告质量评估质量对 ES 的影响可能会产生误导性结果。